MedTrace Logo

Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis

NCT01479231 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2012-04-19

No results posted yet for this study

Summary

The investigators will determine the prevalence of gastroesophageal reflux disease (GERD) in Eosinophilic Esophagitis (EoE) and importantly determine the predictors of response to Proton Pump Inhibitor (PPI) therapy in EoE. Moreover, the investigators will determine the effect of GERD on the location of esophageal eosinophilia.

Conditions

  • Gastroesophageal Reflux Disease
  • Eosinophilic Esophagitis
  • Dysphagia

Interventions

DRUG

dexlansoprazole

Dexlansoprazole 60 mg daily for 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Jeffrey A Alexander, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-03-31
Completion
2012-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01479231 on ClinicalTrials.gov